The Double Hazard of Thrombophilia and Bleeding in Acute Promyelocytic Leukemia

ABSTRACT

Acute promyelocytic leukemia (APL), once highly fatal, has emerged as the most curable subtype of acute myeloid leukemia in adults. Cure is now expected in ~70 to 90% of patients when treatment includes all-trans retinoic acid (ATRA) combined with anthracycline-based chemotherapy. Early mortality most often is due to a severe and often catastrophic bleeding, often intracerebral in location, and remains a major cause of treatment failure. Thrombosis, either at diagnosis or during the course of treatment, may be unrecognized and reflects the complexity of the coagulopathy. The dual phenomenon of bleeding and thrombosis is attributable to at least three processes: disseminated intravascular coagulation; fibrinolysis (generated in part by expression of annexin-II on the APL cell surface); and direct proteolysis of several proteins including fibrinogen and von Willebrand factor. Both ATRA and arsenic trioxide are associated with rapid resolution of the coagulopathy. The use of heparin, once a mainstay of therapy for patients with APL, has been all but abandoned. Preliminary studies suggest no role for the routine use of antifibrinolytic agents. The most important therapeutic strategy is early institution of ATRA at the first suspicion of the diagnosis (without waiting for genetic confirmation) and aggressive blood product support during induction.

KEYWORDS

Acute promyelocytic leukemia - coagulopathy - thrombosis - all-trans retinoic acid - arsenic trioxide

REFERENCES

• 1 Hillestad L K. Acute promyelocytic leukemia.  Acta Med Scand. 1957;  159 189-194
• 2 Kantarjian H M, Keating M J, Walters R S et al.. Acute promyelocytic leukemia: MD Anderson Hospital experience.  Am J Med. 1986;  80 789-797
• 3 Cordonnier C, Vernant J P, Brun B et al.. Acute promyelocytic leukemia in 57 previously untreated patients.  Cancer. 1985;  55 18-25
• 4 Petti M C, Avvisati G, Amadori S et al.. Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients.  Haematologica. 1987;  72 151-155
• 5 Stone R M, Maguire M, Goldberg M A et al.. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.  Blood. 1988;  71 690-696
• 6 Avvisati G, Petti M C, Lo Coco F et al.. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia; final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.  Blood. 2002;  100 3141-3146
• 7 Pittman G R, Senhauser D A, Lowney J F. Acute promyelocytic leukemia: a report of 3 autopsied cases.  Am J Clin Pathol. 1966;  46 214-220
• 8 Daly P A, Schiffer C A, Wiernik P H. Acute promyelocytic leukemia-clinical management in 15 patients.  Am J Hematol. 1980;  8 347-359
• 9 Gralnick H R, Abrell E. Studies of the procoagulant activity of promyelocytes in acute promyelocytic leukemia.  Br J Haematol. 1973;  24 89-99
• 10 Kim H, Lee J-H, Choi S-J et al.. Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients.  Haematologica. 2004;  89 622-624
• 11 Fenaux P, Le Deley M C, Castaigne S et al.. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL Group.  Blood. 1993;  82 3241-3249
• 12 Fenaux P, Chastang C, Chevret S et al.. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.  Blood. 1999;  94 1192-1200
• 13 Tallman M S, Andersen J W, Schiffer C A et al.. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.  Blood. 2002;  100 4298-4302
• 14 Sanz M A, Martin G, Gonzalez M et al.. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group.  Blood. 2004;  103 1237-1243
• 15 Dally N, Hoffman R, Haddad N, Sarig G, Rowe J M, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients.  Thromb Res. 2005;  116 109-114
• 16 Raanani P, Segal E, Levi I et al.. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA-a manifestation of the basic disease or treatment.  Leuk Lymphoma. 2000;  37 605-610
• 17 Escudier S M, Kantarjian H M, Estey E H. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.  Leuk Lymphoma. 1996;  20 435-439
• 18 Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.  Blood. 1992;  79 534-535
• 19 Colovic M, Miljic O, Colovic M, Jankovic G, Stojkovic M. Reversible portal vein thrombosis complicating induction therapy of acute promyelocytic leukemia.  Thromb Res. 2001;  101 101-103
• 20 Torromeo C, Latagliata R, Avvisati G, Petti M C, Mandelli F. Intraventricular thrombosis during all-trans retinoic acid treatment of acute promyelocytic leukemia.  Leukemia. 2001;  15 1311-1313
• 21 Levin M D, Betjes M G, V d Kwast T H, Wenberg B L, Leebeek F W. Acute adrenal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia.  Haematologica. 2003;  88 ECR21
• 22 Kalk E, Goede A, Rose P. Acute arterial thrombosis in acute promyelocytic leukemia.  Clin Lab Haematol. 2003;  25 267-270
• 23 Goldschmidt N, Gural A, Ben-Yehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans retinoic acid (ATRA) for acute promyelocytic leukemia.  Leuk Lymphoma. 2003;  44 1433-1437
• 24 De Stefano V, Sora F, Rossi E et al.. The risk of thrombosis with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.  J Thromb Haemost. 2005;  3 1985-1992
• 25 Breccia M, Avvisati G, Latagliata R et al.. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.  Leukemia. 2007;  3 79-83
• 26 Lou Y, Mai W Y, Jin J. Simultaneous presentation of acute myocardial infarction and acute promyelocytic leukemia.  Ann Hematol. 2006;  85 409-410
• 27 Bauer K A, Rosenberg R D. Thrombin generation in acute promyelocytic leukemia.  Blood. 1984;  64 791-796
• 28 Dombret H, Scrobohi M L, Ghorra P et al.. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.  Leukemia. 1993;  7 2-9
• 29 Watanabe R, Murata M, Takayama N et al.. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS).  Thromb Haemost. 1997;  77 641-645
• 30 Tallman M S, Lefebvre P, Baine R M et al.. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2 1341-1350
• 31 Tallman M S, Hakimian D, Kwaan H C, Rickles F R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.  Leuk Lymphoma. 1993;  11 27-36
• 32 Barbui T, Finazzi G, Falanga A. The impact of all-trans retinoic acid in the coagulopathy of acute promyelocytic leukemia.  Blood. 1998;  91 3093-3102
• 33 Rovelli A, Biondi A, Rajnoldi A C et al.. Microgranular variant of acute promyelocytic leukemia in children.  J Clin Oncol. 1992;  10 1413-1418
• 34 McKenna R W, Parkin J, Bloomfield C D, Dorothy S, Brunning R D. Acute promyelocytic leukemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant.  Br J Haematol. 1982;  50 201-214
• 35 Kiyoi H, Naoe T, Yokota S et al.. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia.  Leukemia. 1997;  11 1447-1452
• 36 Noguera N I, Breccia M, Divona M et al.. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.  Leukemia. 2002;  16 2185-2189
• 37 Gale R E, Hills R, Pizzey A R et al.. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.  Blood. 2005;  106 3768-3776
• 38 Falanga A, Alessio M G, Donati M B et al.. A new procoagulant in acute leukemia.  Blood. 1988;  71 870-875
• 39 Falanga A, Iacoviello L, Evangelista V et al.. Loss of blast cell procoagulant activity and improvement in hemostatic variables in patients with acute promyelocytic leukemia administered all-trans retinoic acid.  Blood. 1995;  86 1072-1081
• 40 Edwards R L, Brande W. Procoagulant activity of the VX2 carcinoma: tissue factor activity is expressed by tumor cells.  Clin Res. 1989;  37 466A
• 41 Andoh K, Sadakata H, Uchiyama T et al.. One-stage method for assay of tissue factor activity of leukemic cell with special reference to disseminated intravascular coagulation.  Am J Clin Pathol. 1990;  93 679-684
• 42 Nawroth P P, Handlet D, Esmon C T, Stern D. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity.  Proc Natl Acad Sci USA. 1986;  83 3460-3464
• 43 Bevilacqua M F, Pober J, Majeau G et al.. Recombinant human tissue necrosis factor induces procoagulant activity in cultures human vascular endothelium: characterization and comparison with interleukin-1.  Proc Natl Acad Sci USA. 1986;  83 4533-4537
• 44 Nachman R L, Hajar K A, Silverstein R L, Dinarello C A. Interleukin-1 induces endothelial cell synthesis of plasminogen activator inhibitor.  J Exp Med. 1986;  163 1595-1599
• 45 Losada R, Espinosa E, Hernandez C, Dorticos E, Hernandez P. Thrombocytosis in patients with acute promyelocytic leukemia during all-trans retinoic acid treatment.  Br J Haematol. 1996;  95 704-705
• 46 Greeno E W, Bach R, Moldow C. Apoptosis is associated with increased cell surface tissue factor procoagulant activity.  Lab Invest. 1996;  75 281-289
• 47 Flynn P D, Byrne C, Baglin T, Weissberg P, Bennett M. Thrombin generation by apoptotic vascular smooth muscle cells.  Blood. 1997;  89 4378-4384
• 48 Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity-implications for coagulation events and antigenic spread is systemic lupus erythematosus.  Proc Natl Acad Sci USA. 1996;  93 1624-1629
• 49 Kwaan H, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer.  Semin Thromb Hemost. 2003;  29 283-290
• 50 Bennett B, Booth N A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination.  Br J Haematol. 1989;  71 511-517
• 51 Sakata Y, Murakami T, Noro A et al.. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.  Blood. 1991;  77 1949-1957
• 52 Dombret H, Scrobohaci M L, Daniel M T et al.. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.  Leukemia. 1995;  9 19-24
• 53 Menell J S, Cesarman G M, Jacovina A T et al.. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340 994-1004
• 54 Kwaan H, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2 306-312
• 55 Brownstein C, Deora A B, Jacovina A T et al.. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages.  Blood. 2004;  103 317-324
• 56 Schmidt W, Egbring R, Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors.  Thromb Res. 1975;  6 315-329
• 57 Federici A B, Falanga A, Lattuada A et al.. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-trans retinoic acid.  Br J Haematol. 1996;  92 733-739
• 58 Federici A B, D'amico E A. The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia.  Leuk Lymphoma. 1998;  31 491-499
• 59 Kini A R, Peterson L C, Tallman M S, Lingen M W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid.  Blood. 2001;  97 3919-3924
• 60 Alimoghaddam K, Shariftabrizi A, Tavangar M et al.. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.  Leuk Lymphoma. 2006;  47 81-88
• 61 Mechtcheriakova D, Wlachos A, Holzmuller H, Binder B R, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.  Blood. 1999;  93 3811-3823
• 62 Degos L, Dombret H, Chomienne C et al.. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.  Blood. 1995;  85 2643-2653
• 63 Chen G Q, Shi X G, Tang W et al.. Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.  Blood. 1997;  89 3345-3353
• 64 Soignet S L, Frankel S R, Douer D et al.. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.  J Clin Oncol. 2001;  19 3852-3860
• 65 Di Bona E, Avvisati G, Castaman G et al.. Early hemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia.  Br J Haematol. 2000;  108 689-695
• 66 Tapiovara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiating therapy of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors.  Blood. 1994;  83 1883-1891
• 67 Zhang X, Zhou H, Wang J et al.. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin-II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.  Thromb Res. 2002;  106 63-70
• 68 Olwill S A, McGlynn H, Gilmore W S, Alexander H D. All-trans retinoic acid-induced downregulation of annexin-II expression in myeloid leukemia call lines is not confined to acute promyelocytic leukemia.  Br J Haematol. 2005;  131 258-264
• 69 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia.GIMEMA retrospective study in 268 consecutive patients.  Blood. 1990;  75 2112-2117
• 70 Keane T J, Gorman A M, O'Connell L G, Fennelly J J. Epsilon-amino-caproic acid in the management of acute promyelocytic leukemia.  Acta Haematol. 1976;  56 202-204
• 71 Schwartz B S, Williams E C, Conlan M G, Mosher D F. Epsilon-animocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency.  Ann Intern Med. 1986;  105 873-877
• 72 Tallman M S, Brenner B, de la Serna J et al.. Meeting report.  Leukemia Res. 2005;  29 347-351
• 73 Hashimoto S, Koike T, Tatawaki W et al.. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid combined with antifibrinolytic therapy for prophylaxis of hemorrhage.  Leukemia. 1994;  8 1113-1115
• 74 Alimoghaddam K, Ghavamzadeh A, Jahani M. Use of NovoSeven for arsenic trioxide-induced bleeding in APL.  Am J Hematol. 2006;  81 720
• 75 Sanz M A, Tallman M S, LoCoco F et al.. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia.  Blood. 2005;  105 3019-3025
• 76 Milligan D W, Grimwade D, Cullis J O et al.. Guidelines on the management of acute myeloid leukemia.  Br J Haematol. 2006;  135 450-474